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CC BY-NC-ND license (http://creativeBackground/purpose: To investigate the correlation between the CHADS2 score and risk of
contrast-induced nephropathy (CIN), we conducted a retrospective study in patients who un-
derwent elective percutaneous coronary intervention (PCI) and compared its accuracy with
previous scoring systems.
Methods: A total of 539 patients who underwent elective PCI were enrolled. Based on their un-
derlying diseases, such as hypertension, diabetes, and kidney disease, CHADS2 score, R2CHADS2
score, and Mehran’s risk score were calculated for each patient. Incidence of CIN was defined
as a rise in serum creatinine >0.5 mg/dL or >25% increase in baseline within 48 hours after PCI.
All study participants were followed up until October 2014, or until the occurrence of major
adverse cardiovascular events (MACEs).ave no conflicts of interest relevant to this article.
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502 R.-H. Chou et al.Results: Overall, 55 cases (10.2%) of CIN and 90 cases (16.7%) of MACEs were identified after
participants were followed up for 1.57  1.46 years. The study cohort was divided into three
groups according to CHADS2 scores: score 0, score 1e2, and score 3e6. In multivariate analysis,
an increase of 1 point in the CHADS2 score was independently associated with a 37% increase in
the risk of CIN (odds ratio, 1.37; 95% confidence interval, 1.00e1.87; pZ 0.048) and a 49% in-
crease in MACEs (hazard ratio, 1.49; 95% confidence interval, 1.18e1.88, p Z 0.001). In pair-
wise comparison, the discriminatory performance of CHADS2 score was not inferior to either
R2CHADS2 score (p Z 0.226) or Mehran’s risk score (p Z 0.075).
Conclusion: CHADS2 score could be a simple and useful predictor for CIN in patients undergoing
elective PCI.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Contrast-induced nephropathy (CIN), an acute kidney injury
that frequently occurs after administration of contrast
media, is a well-known complication of cardiac catheteri-
zation.1 The reported incidence of CIN varies widely in
different populations, ranging from 7% to 25%, depending on
the presence of risk factors.2,3 Its development has been
associated with increased in-hospital and long-term
morbidity and mortality, prolonged hospitalization, and
long-term renal impairment.1 Hence, risk stratification is
important, in order to apply the appropriate extent of pro-
phylactic strategy in high-risk populations. In fact, several
models have been proposed to predict the incidence of CIN.
In 2004, Mehran et al4 reported a scoring system composed of
eight variables, with fair correlation to the risk of CIN. In
2013, Gurm et al5 created a new model comprising 15 vari-
ables, which yielded better discrimination of CIN incidence
than Mehran’s score. Despite the accuracy, these scoring
systems are usually limited by their complexity and require
various examinations to complete the risk stratification.
CHADS2 score is traditionally used for embolic risk stratifi-
cation in patients with atrial fibrillation. The components of
the CHADS2 score, such as age, diabetes, and heart failure,
have also been reported as risk factors for CIN and adverse
cardiac events. A recent study demonstrated that the
CHADS2 score helps to identify patients with poor prognosis
in acute myocardial infarction (MI).6 However, information
about the use of the CHADS2 score to predict CIN is limited.
We conducted this retrospective cohort study to investigate
the correlation between CHADS2 score and risk of CIN in
patients who underwent elective PCI, and to compare the
accuracy of the CHADS2 score with previous scoring systems
in predicting the CIN incidence.Methods
Study population
We initially screened a total of 547 patients who had stable
coronary artery disease (CAD) and who were admitted to the
ward at the Division of Cardiology, Taipei Veterans General
Hospital, Taipei, Taiwan, from October 2009 to August 2014.Patients older than 18 years and scheduled for elective
percutaneous coronary intervention (PCI) were eligible
for this study. The exclusion criterion was end-stage renal
disease, which was defined as creatinine (Cr) clearance
<15mL/min, eitherwith orwithout preexisting dialysis. After
excluding eight patients, 539 patients’ charts were reviewed
in detail to gather data on medical history, including infor-
mation about traditional cardiovascular risk factors (smoking,
hypertension, diabetes mellitus, hyperlipidemia, heart fail-
ure, and chronic kidney disease), previous cardiovascular
events (MI and cerebrovascular disease), current medical
therapy, and preprocedure laboratory examinations.
The CHADS2 score was calculated for each patient by
assigning 1 point each for the following factors: age
>75 years, hypertension, diabetes mellitus, and heart fail-
ure, and 2 points for a previous stroke or transient ischemic
attack. The patients were divided into three groups ac-
cording to their CHADS2 scores: Group 1, score 0; Group 2,
score 1e2; and Group 3, score 3e6. These cutoff values were
determined following a previous study on the risk of stroke.7
The calculation of R2CHADS2 score was the similar to CHADS2
score, with 2 additional points for renal function impairment
(defined as Cr clearance <60 mL/min).8 Mehran’s risk score
(MRS) was also calculated,4 which assigned 5 points for
periprocedural hypotension or usage of intra-aortic balloon
pump (IABP), 5 points for heart failure, 4 points for age
>75 years, 4 points for serum Cr >1.5 mg/dL, 3 points for
anemia, 3 points for diabetes, and 1 point for each 100 mL of
contrast media usage. The flowchart of patient enrollment is
shown in Figure 1. This research was conducted according to
the principles expressed in the Declaration of Helsinki. The
study was approved by the research ethics committee of
Taipei Veterans General Hospital, and all participants pro-
vided their written informed consent.
Definition of CIN and the endpoints
Baseline serum Cr level was defined as that obtained at
admission, and postprocedure Cr was defined as the
maximal value up to 48 hours after PCI. The primary
endpoint of this study was the occurrence of CIN, which was
defined as the elevation of serum Cr  0.5 mg/dL or 25%
in baseline serum Cr. The secondary endpoint was the
mortality at 1 year after the procedure, or the occurrence
Figure 1 Flowchart of patient enrollment.
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target vessel revascularization, nonfatal MI, ischemic
stroke, and death. Target vessel revascularization is
defined as balloon dilatation or stent deployment over a
previously treated lesion. Nonfatal MI is defined as eleva-
tion of cardiac troponin I (>1 ng/mL) with ischemic symp-
toms. Ischemic stroke is defined as the presence of new
neurological defeat with evidence of cerebral infarction as
verified by either computed tomography or magnetic
resonance imaging. All patients received regular follow-up
at the outpatient department, and their medical records
were carefully reviewed.
Statistical analysis
All enrolled patients were divided into three groups ac-
cording to CHADS2 score. Clinical, laboratory, and proce-
dural data were compared with the use of analysis of
variance for continuous variables (expressed as
mean  standard deviation) and chi-square or Fisher’s
exact test for categorical variables (expressed as counts
and percentages). Incidence rate of CIN, 1-year mortality,
and MACEs were calculated for each group. Multivariate
logistic regression (for CIN) as well as multivariate cox
proportional hazard regression (for MACEs) were conducted
to assess the independent effect of the CHADS2 score.
Variables significantly associated with CIN or MACEs, but
not included in the calculation of the CHADS2 score, were
entered into the multivariate model. Survival curves were
generated by the KaplaneMeier method and survival among
groups was compared by use of the log-rank test.
In addition to CHADS2 score, we also calculated the
R2CHADS2 score, which has been previously reported to be a
more accurate predictor of stroke and systemic embolism
than the CHADS2 score in nonalvular atrial fibrillation pa-
tients.8 MRS was also calculated for each patient as it is
currently the most popular and most widely accepted risk
stratification system for CIN.4 For each of the three risk
scoring systems, receiver operating characteristic (ROC)
curves were used to relate the calculated scores to the
incidence of CIN, 1-year mortality, and MACEs. The area
under the ROC curve (AUC), or C-statistic, was used as ameasure of the predictive accuracy of each scoring system.
The criterion value of the scoring system was determined
by the Youden index, sensitivity þ specificity e 1. The
statistical significance of pairwise comparison between two
AUCs was tested with the method of DeLong et al.9 Data
were analyzed using SPSS version 18.0 (SPSS Inc., Chicago,
IL, USA) and MedCalc version 11.4.2.0 (MedCalc Software,
Mariakerke, Belgium). A p value <0.05 was considered to
indicate statistical significance.Results
Patient characteristics and study endpoints
A total of 539 patients (361 males, 67%) were enrolled in
this study, and all study participants were followed up until
October 2014. The mean age of our cohort was
67.6  13.0 years, and the mean CHADS2 score was
1.7  1.2. Table 1 shows the clinical and laboratory data of
each subgroup after grouping by CHADS2 score. The inci-
dence of hypertension, diabetes, history of stroke, and
congestive heart failure were 66%, 39%, 5%, and 12%,
respectively. Patients with higher CHADS2 scores tended to
be older, with more comorbidities, and required more
contrast media in the procedure than those with lower
CHADS2 scores.
A total of 55 patients were diagnosed with CIN within
48 hours after PCI, bringing the incidence rate to 10.2% in
this cohort. Eleven patients (2.0%) died in the 1st year after
the procedure. During the mean follow-up duration of
1.57  1.46 years, 90 cases of MACEs occurred (incidence
rate 16.7%), including 70 cases of target vessel revascular-
ization, 24 cases of nonfatal MI, two cases of ischemic
stroke, and 17 cases of death. The details of CIN and MACEs
for each of the three groups are shown in Table 2. Whether
divided into three or six groups, the categories with higher
CHADS2 score were significantly associated with higher
incidence of both CIN and MACEs (shown in Figure 2). In
order to determine the relationship between CHADS2 scores
and survival free of MACEs, KaplaneMeier survival analysis
was performed, and the results are shown in Figure 3.
Table 1 Baseline characteristics of the study cohort grouping according to CHADS2 score.
CHADS2 Z 0
(n Z 104)
CHADS2 Z 1e2
(n Z 299)
CHADS2 >2
(n Z 136)
p
Age (y) 56.3  10.8 67.1  12.2 77.4  7.8 <0.001
Male, n (%) 70 (67.3%) 195 (65.2%) 96 (70.6%) 0.543
BMI (kg/m2) 24.9  4.1 26.0  4.5 24.9  3.8 0.017
Medical history, n (%)
Smoking 40 (48.9%) 114 (38.1%) 35 (25.7%) 0.031
Hypertension 0 (0%) 227 (75.9%) 128 (94.1%) <0.001
Diabetes mellitus 0 (0%) 103 (34.5%) 108 (79.4%) <0.001
Congestive heart failure 0 (0%) 19 (6.4%) 42 (30.9%) <0.001
Previous myocardial infarction 4 (3.9%) 10 (3.3%) 13 (9.6%) 0.019
Atrial fibrillation 3 (2.9%) 18 (6.0%) 12 (8.8%) 0.164
Previous stroke/TIA 0 (0%) 1 (0.3%) 28 (20.6%) <0.001
Medications, n (%)
Aspirin 51 (49.0%) 145 (48.5%) 81 (59.6%) 0.088
Clopidogrel 11 (10.6%) 44 (14.7%) 30 (22.1%) 0.040
ACEi 0 (0%) 7 (2.3%) 6 (4.4%) 0.087
ARB 4 (3.9%) 67 (22.4%) 42 (30.9%) <0.001
Beta-blocker 17 (16.4%) 72 (24.1%) 38 (27.9%) 0.106
CCB 4 (3.9%) 67 (22.4%) 46 (33.9%) <0.001
Nitrate 32 (30.8%) 130 (43.5%) 71 (52.2%) 0.004
Diuretics 4 (3.9%) 38 (12.7%) 35 (25.7%) <0.001
Statins 17 (16.4%) 79 (26.4%) 41 (30.2%) 0.043
Laboratory data
Creatinine (mg/dL) 1.0  0.2 1.4  1.2 1.7  1.3 <0.001
Total cholesterol (mg/dL) 176.5  35.0 163.7  35.8 158.8  35.9 0.001
Triacylglycerol (mg/dL) 121.4  71.3 129.6  94.7 120.0  86.4 0.513
LDL (mg/dL) 101.7  35.1 94.7  36.0 91.4  29.3 0.080
Uric acid (mg/dL) 5.9  1.6 6.2  1.9 6.4  2.2 0.105
Contrast volume (mL) 92.3  78.9 110.1  79.3 141.5  86.1 <0.001
CHADS2 score 0 1.5  0.5 3.3  0.6 <0.001
R2CHADS2 score 0.2  0.6 2.2  1.1 4.5  1.1 <0.001
Mehran’s score 1.7  2.2 6.1  3.9 12.5  4.1 <0.001
ACEi Z angiotensin-converting enzyme inhibitor; ARB Z angiotensin II receptor blockers; BMI Z body mass index; CCB Z calcium
channel blockers; LDL Z low-density lipoprotein; TIA Z transient ischemic attack.
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For risk stratification, logistic regression analysis was per-
formed for CIN, and Cox proportional hazard analysis was
performed for MACEs. The results are shown in Table 3. An
increase of 1 point in the CHADS2 score was associated with
a 40% significant increase in CIN [odds ratio (OR), 1.40; 95%
confidence interval (CI), 1.12e1.76; p Z 0.004], 151%Table 2 Incidence of contrast-induced nephropathy (CIN), 1-yea
grouping by CHADS2 scores.
Variable CHADS2 Z 0
(n Z 104)
C
(n
CIN incidence (%) 7 (6.7%) 2
1-y mortality (%) 0 4
MACE incidence (%) 5 (4.8%) 4
Revascularization 4 (3.9%) 3
Myocardial infarction 0 1
Ischemic stroke 1 (1.0%) 0
Death 0 5significant increase in 1-year mortality [hazard ratio (HR),
2.51; 95% CI, 1.60e3.92, p <0.001], and 46% significant
increase in 1-year MACEs (HR 1.46; 95% CI, 1.24e1.72,
p < 0.001). To address concerns over confounding variables
affecting the prognostic performance of CHADS2 score, we
also constructed a multivariable analysis. The confounders
age, sex, baseline Cr, and contrast volume were entered
into the multivariable analysis of CIN, whereas ther mortality, and major adverse cardiovascular events (MACEs)
HADS2 Z 1e2
Z 299)
CHADS2 > 2
(n Z 136)
p
5 (8.4%) 23 (16.9%) 0.010
(1.3%) 7 (5.2%) 0.009
6 (15.4%) 39 (28.7%) <0.001
9 (13.0%) 27 (19.9%) 0.001
6 (5.4%) 8 (5.9%) 0.048
1 (0.7%) 0.276
(1.7%) 12 (8.8%) <0.001
Figure 2 (A, B)The incidence of contrast-induced nephropathy (CIN) correlates with CHADS2 scores. (C, D) Major adverse car-
diovascular events (MACEs) correlate with CHADS2 scores. One-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc
test were performed. (*p < 0.05, **p < 0.001.)
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current medicine usage were entered into the multivariable
analysis of 1-year mortality and MACEs. The results showed
that CHADS2 score is an independent predictor for CIN (OR,
1.37; 95% CI, 1.00e1.87; p Z 0.048), 1-year mortality (HR,
2.70; 95% CI, 1.54e4.76; pZ 0.001), and MACEs (HR, 1.49;
95% CI, 1.18e1.88, p Z 0.001) in patients who had under-
gone elective PCI.
To further evaluate individual risk factor’s contribution
to the predictive power of CHADS2 score, we performed
univariate logistic regression analysis for age, hypertension,
diabetes, heart failure, and previous stroke, respectively.
As one component of the R2CHADS2 score, logistic regres-
sion of renal dysfunction (defined as estimated glomerular
filtration rate < 60 mL/min/1.73 m2) was also assessed. As
shown in Table 4, diabetes (OR, 3.06; 95% CI, 1.72e5.47,
p < 0.001), heart failure (OR, 3.10; 95% CI, 1.58e6.10,
p Z 0.001), and renal dysfunction (OR, 2.08; 95% CI,
1.19e3.65, p Z 0.011) were statistically significant risk
factors of CIN. Moreover, when evaluating the association
with MACEs, the ORs of all risk factors were statistically
significant except for those of aging and previous stroke.
Comparison of CHADS2 score, R2CHADS2 score, and
MRS
Table 5 and Tables S1 and S2 show the AUC, criterion value,
sensitivity, and specify, for the CHADS2, R2CHADS2, and
Mehran’s risk scores in predicting CIN, 1-year mortality, andMACEs. Pairwise comparison between AUCs was also per-
formed for each of the two scoring systems. Being more
complex scoring systems, the R2CHADS2 score and MRS
revealed somewhat better discrimination than the CHADS2
score. However, the difference of AUC between the three
scoring systems did not achieve statistical significance. The
R2CHADS2 score even showed better accuracy than MRS in
the prediction of 1-year mortality (shown in Table S1). In
this cohort of 539 patients with stable CAD, the discrimi-
natory performance of the CHAHS2 score in predicting CIN
was not inferior to either the R2CHADS2 score (pZ 0.226) or
the MRS (p Z 0.075). The criterion value was 2 for the
CHADS2 score, the R2CHADS2 score, and 6 for the MRS.
The main results of this study are summarized sche-
matically in Figure 4. We further divided the study popu-
lation into four risk groups according to the CHADS2 score
and R2CHADS2 score. There was good correlation between
CHADS2 score, R2CHADS2 score, and MRS in predicting the
incidence of CIN. According to these scoring systems, we
may identify CAD patients receiving PCI with high, medium,
or low risk of CIN incidence.
Discussion
In this single-center, retrospective study, CHADS2 score was
shown to be accurate and not inferior to MRS in predicting
the occurrence of CIN in stable CAD patients undergoing
elective PCI. In addition, the CHADS2 score also showed
good prognostic value for the prediction of adverse cardiac
Figure 3 Data of patients grouped by CHADS2 scores. (A) KaplaneMeier curves of freedom from revascularization. (B) Nonfatal
myocardial infarction. (C) Death. (D) Adverse cardiac events.
506 R.-H. Chou et al.events. Given the simplicity of clinical application, pro-
phylaxis against CIN and intensive follow-up should be
provided to medium- to high-risk populations, who had a
CHADS2 score of more than 2, or MRS of more than 6 (shown
in Figure 4).
The CHADS2 score was initially developed for stroke risk
stratification in the atrial fibrillation population.10 As a
convenient scoring system to evaluate complex comobid-
ities, the CHADS2 score and its extended scoring systemsTable 3 Logistic regression analysis for CHADS2 score to contr
analysis for CHADS2 score to 1-year mortality and major adverse
Variable
Univariate
HR (95% CI)
CIN incidence (odds ratio) 1.40 (1.12e1.76)
1-y mortality (hazard ratio) 2.51 (1.60e3.92)
MACE incidence (hazard ratio) 1.46 (1.24e1.72)
Revascularization 1.34 (1.11e1.62)
Myocardial infarction 1.30 (0.95e1.79)
Death 2.43 (1.73e3.40)
CI Z confidence interval; HR Z hazard ratio.
a Adjusted for age, sex, baseline Cr, and contrast volume.
b Adjusted for age, sex, previous myocardial infarction, smoking st
converting enzyme inhibitor, angiotensin II receptor blockers, beta-bare popular in clinical research and have reportedly been
applied to evaluate the risk of new-onset atrial fibrilla-
tion,11 incidence of pulmonary embolism,12 severity of pe-
ripheral arterial disease,13 and prognosis of MI.6 To the best
of our knowledge, this is the first study to investigate the
use of CHADS2 score to predict the occurrence of CIN.
CIN is regarded as acute kidney injury after exposure to
radiocontrast media, and is caused by renal vasoconstric-
tion,14 endothelium cell damage,15 followed by renalast-induced nephropathy (CIN), and Cox proportional hazard
cardiovascular events (MACEs).
CHADS2 score
Multivariate
p HR (95% CI) p
0.004 1.37 (1.00e1.87)a 0.048a
<0.001 2.70 (1.54e4.76)b 0.001b
<0.001 1.49 (1.18e1.88)b 0.001b
0.002 1.45 (1.12e1.88)b 0.006b
0.102 1.07 (0.65e1.75)b 0.802b
<0.001 2.25 (1.33e3.83)b 0.003b
atus, and medications includes aspirin, clopidogrel, angiotensin-
locker, and statin.
Table 4 Logistic regression analysis for individual predictor of CHADS2 score and R2CHADS2 score.
Variable Contrast-induced nephropathy MACEs
OR (95% CI) p OR (95% CI) p
Age >75 y 1.41 (0.80e2.46) 0.233 1.51 (0.96e2.38) 0.076
HTN 1.05 (0.58e1.91) 0.863 3.25 (1.78e5.92) <0.001
DM 3.06 (1.72e5.47) <0.001 2.24 (1.41e3.54) 0.001
CHF 3.10 (1.58e6.10) 0.001 3.31 (1.85e5.91) <0.001
Stroke 0.64 (0.15e2.76) 0.548 1.32 (0.52e3.35) 0.555
eGFR<60 2.08 (1.19e3.65) 0.011 2.12 (1.34e3.35) 0.001
CHADS2 score 1.40 (1.12e1.76) 0.004 1.65 (1.36e2.01) <0.001
R2CHADS2 score 1.31 (1.12e1.53) 0.001 1.42 (1.24e1.62) <0.001
CHF Z congestive heart failure; CI Z confidence interval; DM Z diabetes mellitus; eGFR Z estimated glomerular filtration rate;
HTN Z hypertension; MACEs Z major adverse cardiovascular events; OR Z odds ratio.
CHADS2 score predicts contrast-induced nephropathy 507tubular injury16,17 and medullary hypoxia.18,19 Although CIN
is generally benign, in most instances it is associated with
extended length of hospital stays, increased healthcare
costs, and higher risk of death.20 It is not surprising that the
CHADS2 score is associated with CIN as all five components
of the CHADS2 score are either risk factors for atheroscle-
rosis or presentation of peripheral arterial disease. In
particular, advanced age,21 diabetes mellitus,22 heart fail-
ure,22 and renal dysfunction19 are already well-known risk
factors for CIN. Even hypertension and high central pulse
pressure have been reported to be associated with
increased CIN incidence.23,24 These risk factors are also
part of the components of MRS, which may explain the
close correlation between CHADS2 score and MRS in our
study.
Mehran et al4 investigated a cohort of 5571 patients who
underwent PCI [35.7% with acute coronary syndrome
(ACS)], and established a popular scoring system for risk
stratification for CIN. MRS comprised eight variables,
including hypotension, use of IABP, heart failure, age older
than 75 years, anemia, diabetes, serum Cr of more than
1.5 mg/dL, and contrast volume. Because of its simplicity,
MRS is currently the most widely used tool to predict the
risk of CIN in patients who have undergone PCI. Our study is
the first to show that in a stable CAD cohort, not including
patients undergoing cardiogenic shock or using IABP, the
discriminating ability of the CHADS2 score and that of MRS
are similar. This makes CHADS2 score an acceptable tool for
CIN risk stratification in patients with stable CAD.
Compared to MRS, CHADS2 score is simpler, comprising onlyTable 5 The C-statistic of CHARS2 score, R2CHADS2 score, MRS; a
prediction the incidence of CIN.
AUC Criterion v
CHADS2 score 0.605 >2
R2CHADS2 score 0.629 >2
MRS 0.650 >6
Pairwise comparison of AUC (9
CHADS2 vs. R2CHADS2 0.024 (0.015 to 0.063)
CHADS2 vs. MRS 0.044 (0.005 to 0.093)
R2CHADS2 vs. MRS 0.020 (0.002 to 0.059)
AUC Z area under receiver operating characteristic curve; CI Z
MRS Z Mehran’s risk score.five clinical variables. All factors required to calculate the
CHADS2 score could be obtained from the patient’s medical
history, allowing physicians to conduct preliminary risk
evaluation prior to performing PCI. Moreover, the CHADS2
score is useful in predicting short-term cardiac outcome in
CAD patients who have received PCI.
As a tool for CIN risk stratification, the CHADS2 score has
at least two weak points. The first one is its low sensitivity.
This could be overcome by further assessment of pre-
procedure renal function. When adding renal dysfunction
into consideration, the R2CHADS2 score would have similar
sensitivity and specificity with the MRS (as shown in Table
5). Another weak point is the inconsistency of the pre-
dicting power of individual risk factors and its weighted
score. As shown in Table 4, when evaluating the association
of CIN, only the ORs of diabetes, heart failure, and renal
dysfunction were statistically significant. The OR of previ-
ous stroke did not achieve statistical significance, but it was
calculated as 2 points, much more than that for diabetes
and heart failure. After all, CHADS2 was originally designed
for risk stratification of stroke rather than acute kidney
injury. The aim of this study is to provide a simple method
to evaluate the risk of CIN rather than creating a whole new
scoring system. Because of its simplicity and convenience,
CHADS2 is still a valuable predictor for CIN.
There are several limitations in our study. First of all,
this is a retrospective study, which limits the generalization
of its findings. Second, we did not enroll patients with ACS.
Compared to Mehran et al’s study and other studies with
ACS participants,25 the incidence of CIN is lower in ournd pairwise comparison of the accuracy of the three scores in
alue Sensitivity (%) Specificity (%)
41.82 76.65
65.45 58.88
76.36 54.96
5% CI) p
0.226
0.075
0.303
confidence interval; CIN Z contrast-induced nephropathy;
Figure 4 Risk stratification of contrast-induced nephropathy
(CIN) according to CHADS2 score, R2CHADS2 score, and Mehran’s
risk score.
508 R.-H. Chou et al.cohort, and the result may not be generalized to all pa-
tients. Third, the small study population may also lead to
somewhat inaccurate results. For example, the decreased
MACE incidence in CHADS2 score 5e6 group was a typical
error caused by small case numbers (Figure 2). After we
divided the study cohort into six groups according to
CHADS2 score, the CHADS2 score 4 group comprised only 27
patients, and the CHADS2 score 5e6 group comprised only
six patients. Nevertheless, there was an obvious trend that
MACE incidence increased with CHADS2 score. In addition,
lacking the results of certain examinations, the comparison
of CHADS2 score and certain other scoring systems could not
be fully realized. For example, Capodanno et al26 provided
a formula, the ACEF score (which stands for age, creati-
nine, and ejection fraction), to calculate CIN incidence by
using age, serum Cr, and left ventricular ejection fraction.
Because not all of our patients had echocardiogram data,
we could not compare the accuracy of CHADS2 score and
ACEF score. Finally, some confounders of CIN, such as
periprocedural hydration, proteinuria, and nephrotoxic
agents, could not be fully accessed and adjusted in our
study because of the limited availability of data fields.
Although discrimination performance is a desirable
property when a score is designed, user-friendliness is also
important to make the system applicable in daily clinical
practice. For patients with stable CAD, the CHADS2 score is
a simple risk score for bedside, preprocedure CIN risk
stratification. It also offers opportunities to develop more
effective prophylactic strategies. In conclusion, the CHADS2
score is useful to predict the incidence of CIN.
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KaplaneMeier curves of 1-year mortality in patients
grouped by CKD severity suggested that the mortality rate
of stage 4e5 CKD patients was significantly higher than the
other groups.
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